Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis A-hepatitis B vaccine - GlaxoSmithKline

Drug Profile

Hepatitis A-hepatitis B vaccine - GlaxoSmithKline

Alternative Names: Ambirix; Twinrix; Twinrix Adult; Twinrix Paediatric; Twinrix® Junior

Latest Information Update: 22 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Hepatitis A vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis A; Hepatitis B

Most Recent Events

  • 22 Jan 2019 Launched for Hepatitis A (In adolescents, In children, In infants, Prevention) in Iceland, Norway (IM) before January 2019 (EMA website)
  • 22 Jan 2019 Launched for Hepatitis A (Prevention) in Iceland (IM) before January 2019 (EMA website)
  • 22 Jan 2019 Launched for Hepatitis B (In adolescents, In children, In infants, Prevention) in Norway, Iceland (IM) before January 2019 (EMA website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top